Oral antidiabetics: [with 85 tables]
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Berlin [u.a.]
Springer
1996
|
| Schriftenreihe: | Handbook of experimental pharmacology
119 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XXXI, 732 S. Ill., graph. Darst. |
| ISBN: | 3540589902 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV010484019 | ||
| 003 | DE-604 | ||
| 005 | 20140403 | ||
| 007 | t | ||
| 008 | 951113s1996 gw ad|| |||| 00||| eng d | ||
| 016 | 7 | |a 944730914 |2 DE-101 | |
| 020 | |a 3540589902 |9 3-540-58990-2 | ||
| 035 | |a (OCoLC)32859225 | ||
| 035 | |a (DE-599)BVBBV010484019 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c DE | ||
| 049 | |a DE-19 |a DE-355 |a DE-12 |a DE-20 |a DE-11 |a DE-188 |a DE-578 | ||
| 050 | 0 | |a QP905 | |
| 050 | 0 | |a RC661.A1 | |
| 082 | 0 | |a 615/.1 |2 20 | |
| 082 | 0 | |a 616.4/62061 |2 20 | |
| 084 | |a VT 5200 |0 (DE-625)147743:253 |2 rvk | ||
| 084 | |a XI 1701 |0 (DE-625)152977:12907 |2 rvk | ||
| 084 | |a YC 6800 |0 (DE-625)153250:12905 |2 rvk | ||
| 084 | |a MED 441f |2 stub | ||
| 084 | |a MED 970f |2 stub | ||
| 084 | |a QV 4 |2 nlm | ||
| 084 | |a MED 920f |2 stub | ||
| 245 | 1 | 0 | |a Oral antidiabetics |b [with 85 tables] |c contributors H. J. Ahr ... Ed. Jochen Kuhlmann ... |
| 264 | 1 | |a Berlin [u.a.] |b Springer |c 1996 | |
| 300 | |a XXXI, 732 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Handbook of experimental pharmacology |v 119 | |
| 650 | 7 | |a Drugs |2 cabt | |
| 650 | 7 | |a Hypoglycaemic Properties |2 cabt | |
| 650 | 7 | |a Antidiabetica |2 gtt | |
| 650 | 7 | |a Orale toediening |2 gtt | |
| 650 | 4 | |a Diabetes Mellitus, Type 2 |x drug therapy | |
| 650 | 4 | |a Hypoglycemic Agents |x pharmacology | |
| 650 | 4 | |a Hypoglycemic Agents |x therapeutic use | |
| 650 | 4 | |a Hypoglycemic agents | |
| 650 | 4 | |a Non-insulin-dependent diabetes |x Chemotherapy | |
| 650 | 0 | 7 | |a Diabetes mellitus |0 (DE-588)4070446-4 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Antidiabetikum |0 (DE-588)4002265-1 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Orale Applikation |0 (DE-588)4202348-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Pharmakotherapie |0 (DE-588)4076066-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |a Orales Antidiabetikum |2 gnd |9 rswk-swf | |
| 689 | 0 | 0 | |a Antidiabetikum |0 (DE-588)4002265-1 |D s |
| 689 | 0 | 1 | |a Orale Applikation |0 (DE-588)4202348-8 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Diabetes mellitus |0 (DE-588)4070446-4 |D s |
| 689 | 1 | 1 | |a Pharmakotherapie |0 (DE-588)4076066-2 |D s |
| 689 | 1 | |5 DE-604 | |
| 689 | 2 | 0 | |a Antidiabetikum |0 (DE-588)4002265-1 |D s |
| 689 | 2 | |5 DE-604 | |
| 689 | 3 | 0 | |a Orales Antidiabetikum |A f |
| 689 | 3 | |5 DE-604 | |
| 700 | 1 | |a Kuhlmann, Jochen |e Sonstige |4 oth | |
| 700 | 1 | |a Ahr, Hans Jürgen |e Sonstige |4 oth | |
| 830 | 0 | |a Handbook of experimental pharmacology |v 119 |w (DE-604)BV002390716 |9 119 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006986806&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-006986806 | ||
Datensatz im Suchindex
| _version_ | 1804124918157148160 |
|---|---|
| adam_text | J ORAL ANTIDIABETICS CONTRIBUTORS H.J. AHR, S.L. ALI, J.M. AMATRUDA,
E.M. BARDOLPH, H. BISCHOFF, H.H. BLUME, E.-M. BOMHARD, E. BRENDEL, L.
GROOP, F. HARTIG, A. HASSELBLATT, L.S. HERMANN, B. JUNGE, J. KOBBERLING,
H.P. KRAUSE, J. KUHLMANN, K.H. LANGER, H.E. LEBOVITZ, P.J. LEFEBVRE, M.
MATZKE, M.L. MCCALEB, G. NEUGEBAUER, M. NOEL, P. OCHLICH, U. PANTEN,
H.J. PLOSCHKE, H. PLIIMPE, E. PRUGNARD, W. PULS, W. REBEL, A.J. SCHEEN,
H. SCHLECKER, F.H. SCHMIDT, B.S. SCHUG, E. SCHIITZ, C. SCHWANSTECHER, M.
SCHWANSTECHER, S. SEIP, J. STOLTEFUSS, R.H. TAYLOR, N.F. WIERNSPERGER,
W. WINGENDER, C. WIINSCHE EDITORS JOCHEN KUHLMANN AND WALTER PULS
SPRINGER IF. CONTENTS CHAPTER 1 INTRODUCTION J. KUHLMANN 1 REFERENCES 5
CHAPTER 2 PATHOPHYSIOLOGY OF TYPE 2 DIABETES MELLITUS A.J. SCHEEN AND
P.J. LEFEBVRE. WITH 5 FIGURES 7 A. INTRODUCTION 7 I. HETEROGENEOUS
DISEASE 7 II. GENETIC BACKGROUND 8 III. ENVIRONMENTAL FACTORS 8 B.
ABNORMALITIES OF THE GLUCOSE-INSULIN FEEDBACK LOOP 9 I. INSULIN
SECRETION 10 1. HOW TO MEASURE INSULIN SECRETION? 11 2. ABNORMAL PLASMA
CONCENTRATIONS 12 3. ABNORMAL KINETICS RESPONSE 13 4. VARIA 14 II.
INSULIN SENSITIVITY 14 1. HEPATIC GLUCOSE PRODUCTION 14 2. SPLANCHNIC
GLUCOSE UPTAKE 16 3. PERIPHERAL (MUSCLE) GLUCOSE UPTAKE 16 4. ADIPOSE
TISSUE LIPOLYSIS 18 5. INCREASED GLUCAGON SECRETION 19 6. VARIA 19 C.
POSSIBLE CAUSAL DEFECTS 19 I. INSULIN SECRETION 19 1. B-CELL NUMBER 19
2. INSULIN GENE 20 3. AMYLIN 21 4. GLUT 2 21 5. GLUCOKINASE 21 XII
CONTENTS 6. ACCUMULATION OF B-CELL GLYCOGEN 22 7. VARIA 22 II. INSULIN
SENSITIVITY 23 1. INSULIN PRE-RECEPTOR LEVEL 23 2. INSULIN RECEPTOR
LEVEL 24 3. INSULIN POST-RECEPTOR LEVEL 25 4. VARIA ,. 28 D. ROLE OF
ASSOCIATED OBESITY 29 I. IMPACT OF OBESITY ON INSULIN SECRETION 29 II.
IMPACT OF OBESITY ON INSULIN SENSITIVITY 29 III. LIPID OXIDATION AND
INSULIN RESISTANCE 30 IV. FROM OBESITY TO TYPE 2 DIABETES 30 E. DYNAMIC
INTERACTION BETWEEN INSULIN ACTION AND INSULIN SECRETION 31 I. WHAT IS
THE PRIMARY DEFECT? 31 II. TRANSIENT COMPENSATORY MECHANISMS 32 III.
ROLE OF GLUCOSE TOXICITY 33 IV. VICIOUS CIRCLE LEADING TO SEVERE
HYPERGLYCAEMIA 33 F. CONCLUSIONS 34 REFERENCES 35 CHAPTER 3
NON-PHARMACOLOGICAL MANAGEMENT OF NON-INSULIN-DEPENDENT DIABETES J.
KOBBERLING 43 A. DIETARY MANAGEMENT 43 I. GENERAL BASIS FOR
RECOMMENDATIONS 43 II. TOTAL ENERGY INTAKE 44 1. OVERWEIGHT NIDDM
PATIENTS 44 2. NORMAL WEIGHT NIDDM PATIENTS 45 III. CARBOHYDRATES 46 1.
DIETARY FIBRES 46 2. SIMPLE SUGARS 48 3. GLYCAEMIC INDEX OF VARIOUS
CARBOHYDRATES 48 IV. DIETARY FAT 49 V. DIETARY PROTEIN 50 VI. OTHER
DIETARY FACTORS 51 1. SODIUM 51 2. ALCOHOL 51 3. VITAMINS, MINERALS AND
TRACE ELEMENTS : 51 VII. DIETARY SPECIALITIES FOR DIABETICS 52 1.
SWEETENERS : 52 2. DIABETIC FOODS 52 CONTENTS XIII VIII. PROBLEMS AND
TECHNIQUES OF DIETARY ADVICE 52 IX. DIETARY RECOMMENDATIONS IN
NON-WESTERN SOCIETIES ... 53 1. INDIA AND SOUTHEAST ASIA 53 2. JAPAN
54 3. CHINA 55 4. AFRICA 55 B. EXERCISE 55 I. INSULIN-DEPENDENT DIABETES
56 II. NON-INSULIN-DEPENDENT DIABETES 56 1. SHORT-TERM EFFECTS 56 2.
LONG-TERM EFFECTS 57 III. RECOMMENDATIONS 58 REFERENCES 59 SECTION I:
SULFONYLUREAS CHAPTER 4 SULFONYLUREAS AND RELATED COMPOUNDS: CHEMISTRY
AND STRUCTURE-ACTIVITY RELATIONSHIPS H. PLUMPE. WITH 1 FIGURE 65 A.
INTRODUCTION 65 B. SULFONYLUREAS 7 66 I. VARIATION OF R 1 66 II.
VARIATION OF R 2 69 C. SULFONYLSEMICARBAZIDES 69 D.
SULFONYLAMINOPYRIMIDINES 69 E. VARIOUS NONMARKETED COMPOUNDS OF INTEREST
69 F. CONCLUSIONS 71 REFERENCES 71 CHAPTER 5 SULFONYLUREAS:
PHYSICOCHEMICAL PROPERTIES, ANALYTICAL METHODS OF DETERMINATION AND
BIOAVAILABILITY S.L. ALI, H.H. BLUME, AND B.S. SCHUG. WITH 15 FIGURES 73
A. INTRODUCTION 73 B. PHYSICAL PROPERTIES 73 I. DESCRIPTION 73 II.
MELTING POINT 73 XIV CONTENTS III. SOLUBILITY 73 1. ACETOHEXAMIDE 76 2.
ACETYLCARBUTAMIDE 76 3. CARBUTAMIDE 77 4. CHLORPROPAMIDE 77 5.
GLIBENCLAMIDE 77 6. GLIMEPIRIDE 77 7. GLIPIZIDE 77 8. GLIQUIDONE 77 9.
GLISOXEPIDE 77 10. METAHEXAMIDE 78 11. TOLAZAMIDE 78 12. TOLBUTAMIDE 78
IV. DISSOCIATION CONSTANTS 79 V. CRYSTAL SHAPE AND STRUCTURE 79 1.
ACETOHEXAMIDE 79 2. GLIMEPIRIDE 80 3. TOLBUTAMIDE 80 C. ULTRAVIOLET
SPECTRUM 82 D. INFRARED SPECTRUM 82 E. NUCLEAR MAGNETIC RESONANCE
SPECTRUM 86 F. MASS SPECTRUM 86 G. COLOR AND IDENTIFICATION REACTIONS 88
I. ACETOHEXAMIDE, GLIBORNURIDE, GLIQUIDONE 91 II. CARBUTAMIDE 91 III.
CHLORPROPAMIDE 91 IV. GLIBENCLAMIDE 91 V. TOLBUTAMIDE 91 H. STABILITY
AND DEGRADATION 92 I. ACETOHEXAMIDE 92 II. CHLORPROPAMIDE 92 III.
GLIBENCLAMIDE 92 IV. GLIMPIRIDE 93 V. GLISOXEPIDE 93 VI. TOLBUTAMIDE 93
I. METHODS OF ANALYSIS 94 I. TITRIMETRY 94 1. ACETOHEXAMIDE 94 2.
CARBUTAMIDE 94 3. CHLORPROPAMIDE 95 4. GLIBENCLAMIDE 95 5. GLIPIZIDE 95
6. GLISOXEPIDE 95 7. TOLAZAMIDE 95 8. TOLBUTAMIDE 95 CONTENTS XV II.
ULTRAVIOLET SPECTROPHOTOMETRY 96 1. ACETOHEXAMIDE 96, 2. CARBUTAMIDE 96
3. CHLORPROPAMIDE 96 4. GLIBENCLAMIDE 96 5. GLIPIZIDE 96 6. TOLBUTAMIDE
97 III. COLORIMETRIC METHODS 97 1. CARBUTAMIDE 97 2. GLIBENCLAMIDE 97 3.
TOLBUTAMIDE 98 IV. FLUORIMETRY 98 V. MISCELLANEOUS METHODS 98 J.
CHROMATOGRAPHIC METHODS 98 I. PAPER CHROMATOGRAPHY 99 II. THIN-LAYER
CHROMATOGRAPHY 99 III. GAS-LIQUID CHROMATOGRAPHY AND MASS SPECTROMETRY
99 1. ACETOHEXAMIDE 99 2. CHLORPROPAMIDE 99 3. GLIBENCLAMIDE 103 4.
TOLAZAMIDE 103 5. TOLBUTAMIDE 103 IV. HIGH-PERFORMANCE LIQUID
CHROMATOGRAPHY 104 1. ACETOHEXAMIDE, CHLORPROPAMIDE, GLIBORNURIDE,
GLICLAZIDE, TOLAZAMIDE 104 2. CARBUTAMIDE 106 3. GLIBENCLAMIDE,
GLIPIZIDE 106 4. GLIMEPIRIDE 107 5. GLISOXEPIDE 108 6. TOLBUTAMIDE 108
K. BIOAVAILABILITY 108 1. ACETOHEXAMIDE ILL 2. CHLORPROPAMIDE ILL 3.
GLIBENCLAMIDE (GLYBURIDE) 113 4. GLICLAZIDE 115 5. GLIMEPIRIDE 117 6.
GLIPIZIDE 117 7. GLIQUIDONE 118 8. GLISOXEPIDE 119 9. TOLAZAMIDE 119 10.
TOLBUTAMIDE 119 REFERENCES 121 XVI CONTENTS CHAPTER 6 MODE OF ACTION OF
SULFONYLUREAS U. PANTEN, M. SCHWANSTECHER, AND C. SCHWANSTECHER. WITH 3
FIGURES 129 A. INTRODUCTION 129 B. ACTIONS ON PANCREATIC /? CELLS 130 I.
STIMULATION OF INSULIN SECRETION 130 II. INHIBITION OF THE K ATP CHANNEL
131 III. LOCATION OF THE SULFONYLUREA RECEPTOR 134 IV. PROPERTIES OF THE
BINDING SITES FOR SULFONYLUREAS 135 V. STRUCTURE OF COMPOUNDS
INTERACTING WITH THE SULFONYLUREA RECEPTOR 140 C. ACTIONS ON NON-/?
CELLS IN PANCREATIC ISLETS 143 D. ACTIONS ON NEURONS 144 E. ACTIONS ON
CARDIAC CELLS 145 F. ACTIONS ON SMOOTH MUSCLE 147 G. ACTIONS ON SKELETAL
MUSCLE 147 H. ACTIONS ON MISCELLANEOUS CELLS 148 I. CONCLUSIONS 148
REFERENCES 149 CHAPTER 7 SULFONYLUREAS: PHARMACOKINETICS IN ANIMAL
EXPERIMENTS A. HASSELBLATT ...: 161 A. INTRODUCTION 161 B. ABSORPTION OF
SULFONYLUREA DERIVATIVES AFTER ORAL ADMINISTRATION 162 I. SPECIES
DIFFERENCES IN THE RATE OF ABSORPTION 162 II. KINETICS OF ABSORPTION OF
SULFONYLUREAS AND EFFECTS OF FOOD AND OTHER DRUGS 163 III. DEPENDENCE OF
ABSORPTION ON GALENIC FORMULATION 164 C. DISTRIBUTION OF SULFONYLUREA
DERIVATIVES IN THE ORGANISM 164 I. SPACE OF DISTRIBUTION OF SULFONYLUREA
DERIVATIVES 164 II. PROTEIN BINDING OF SULFONYLUREAS AND INTERACTION
WITH OTHER COMPOUNDS ON PLASMA PROTEIN-BINDING SITES . . 167 D.
ACCUMULATION OF SULFONYLUREA DERIVATIVES IN DIFFERENT ORGAN SYSTEMS 169
I. ACCUMULATION IN THE LIVER . 169 II. ACCUMULATION OF SULFONYLUREA
DERIVATIVES IN THE PANCREATIC ISLETS 169 E. ELIMINATION OF SULFONYLUREA
DERIVATIVES 171 CONTENTS XVII F. INFLUENCE OF OTHER DRUGS ON RATE OF
METABOLISM AND EXCRETION OF SULFONYLUREA DRUGS 175 G. POSSIBLE
IMPLICATIONS OF THE RESULTS FROM ANIMAL EXPERIMENTS ON THE
PHARMACOKINETICS OF SULFONYLUREA DERIVATIVES FOR CLINICAL APPLICATIONS
IN HUMANS 176 REFERENCES 178 CHAPTER 8 TOXICOLOGY OF SULFONYLUREAS F.
HARTIG, K.H. LANGER, W. REBEL, F.H. SCHMIDT, AND E. SCHUTZ 185 A.
INTRODUCTION 185 B. ACUTE TOXICITY 185 C. CHRONIC TOXICITY 187 I.
CARBUTAMIDE 187 1. RATS 187 2. DOGS 187 II. TOLBUTAMIDE 187 III.
CHLORPROPAMIDE .; 188 1. RATS AND MICE 188 2. DOGS 188 IV. ACETOHEXAMIDE
189 V. TOLAZAMIDE 189 VI. GLIBENCLAMIDE 189 VII. GLICLAZIDE 189 VIII.
GLIPIZIDE 190 IX. GLIQUIDONE 190 X. GLIBORNURIDE 190 XI. GLISOXEPIDE 190
1. SUBCHRONIC AND CHRONIC TOXICITY IN RATS 190 2. CHRONIC TOXICITY IN
DOGS 191 D. REPRODUCTION TOXICOLOGY 191 I. GLIBENCLAMIDE 191 II.
GLISOXEPIDE 192 III. GLIQUIDONE 192 IV. GLIBORNURIDE 192 E. MUTAGENICITY
192 F. OTHER TOXICOLOGICAL STUDIES 193 I. IN VIVO STUDIES 193 II. IN
VITRO STUDIES 194 G. CONCLUSIONS 196 REFERENCES 196 XVIII CONTENTS
CHAPTER 9 CLINICAL PHARMACOLOGY OF SULFONYLUREAS L. GROOP AND G.
NEUGEBAUER. WITH 3 FIGURES 199 A. PHARMACODYNAMICS 199 I. MODE OF ACTION
OF SULFONYLUREAS 199 1. EFFECTS ON INSULIN SECRETION 199 II. HEPATIC
INSULIN CLEARANCE 203 III. OTHER PANCREATIC EFFECTS 203 IV.
EXTRAPANCREATIC EFFECTS 204 V. COMBINATION OF INSULIN AND SULFONYLUREA
205 VI. RATIONAL USE OF SULFONYLUREA DRUGS 206 B. PHARMACOKINETICS 207
I. SIMILARITIES AND DIFFERENCES 207 II. TIMING OF DRUG INTAKE 208 III.
EFFECT OF HYPERGLYCEMIA 211 IV. DOSE- AND CONCENTRATION-RESPONSE
RELATIONSHIP 211 1. FIRST-PHASE INSULIN SECRETION 212 2. SECOND-PHASE
INSULIN SECRETION 213 3. FASTING BLOOD GLUCOSE 213 4. POSTPRANDIAL BLOOD
GLUCOSE 214 5. EUGLYCEMIC AND HYPERGLYCEMIC CLAMP 215 V. SPECIFIC
PHARMACOKINETICS 216 1. CHLORPROPAMIDE 216 2. GLIBENCLAMIDE 218 3.
GLICLAZIDE 221 4. GLIPIZIDE 223 5. TOLBUTAMIDE 225 6. TOLAZAMIDE 227 7.
GLIBORNURIDE 228 8. GLIQUIDONE 229 9. ACETOHEXAMIDE 231 10. GLISOXEPIDE
232 11. GLYCLOPYRAMIDE 232 12. GLYMIDINE SODIUM 232 13. CARBUTAMIDE 233
14. GLIPENTIDE 234 15. DRUGS UNDER CLINICAL INVESTIGATION 234 C. SAFETY
AND TOLERANCE 235 I. HYPOGLYCEMIA 235 II. SULFONYLUREA FAILURE 235 III.
OTHER ADVERSE EFFECTS 236 IV. INTERACTIONS 237 REFERENCES 237 CONTENTS
XIX SECTION II: BIGUANIDES CHAPTER 10 CHEMISTRY AND STRUCTURE-ACTIVITY
RELATIONSHIPS OF BIGUANIDES E. PRUGNARD AND M. NOEL 263 A. INTRODUCTION
263 I. THE FIRST KNOWN SYNTHESIS 263 II. THE GOLDEN AGE 264 III.
NOMENCLATURE 264 IV. NEW ANTIHYPERGLYCEMIC BIGUANIDES 266 B. CHEMISTRY
267 I. SYNTHESIS 267 1. UNSUBSTITUTED BIGUANIDES 269 2.
N-MONOSUBSTITUTED AND N,N-DISUBSTITUTED BIGUANIDES 269 3.
N,N -SUBSTITUTED BIGUANIDES 270 4. N,N -SUBSTITUTED BIGUANIDES 270 5.
N,N N ,N -SUBSTITUTED BIGUANIDES 271 II. STABILITY DEGRADATION 272 1.
THERMAL DECOMPOSITION 272 2. ACTION OF MINERAL ACIDS 272 3. ACTION OF
ALKALIS 273 4. ACTION OF REDUCING AGENTS 273 5. ACTION OF OXIDIZING
AGENTS 273 III. CYCLIZATION REACTIONS 274 1. CYCLIZATION WITH
DERIVATIVES OF CARBOXYLIC ACIDS 274 2. CYCLIZATION WITH CARBONYL
COMPOUNDS 274 3. CYCLIZATION WITH /?-DIFUNCTIONAL COMPOUNDS 275 4.
CYCLIZATION WITH BENZIL OR BENZOIN 276 5. MISCELLANEOUS CYCLIZATIONS 276
IV. METAL-BIGUANIDE COMPLEXES 277 1. SYNTHESIS AND STRUCTURE 277 2.
PHARMACOLOGICAL ACTIVITY OF COMPLEXES 279 3. USE OF BIGUANIDE COMPLEXES
IN ANALYTICAL PROCEDURES 280 C. STRUCTURE-ACTIVITY RELATIONSHIPS 280
REFERENCES 282 XX CONTENTS CHAPTER 11 PHYSICOCHEMICAL PROPERTIES AND
ANALYTICAL METHODS OF DETERMINATION OF BIGUANIDES E. PRUGNARD AND M.
NOEL. WITH 3 FIGURES 287 A. PHYSICAL PROPERTIES 287 I. GENERAL
PROPERTIES 287 II. DISSOCIATION.CONSTANTS 287 III. SPECTROSCOPIC DATA
290 1. ULTRAVIOLET SPECTRA 290 2. INFRARED SPECTRA 291 3. NUCLEAR
MAGNETIC RESONANCE SPECTRA 292 IV. CRYSTAL STRUCTURES AND PROTONATION
SITES 292 1. PHENFORMIN 292 2. METFORMIN 292 B. QUANTITATIVE
DETERMINATION IN BIOLOGICAL MEDIUM 296 I. DETECTION OF ANTIDIABETIC
BIGUANIDES BY SPECTROPHOTOMETRY 296 II. FROM MICROGRAMS TO NANOGRAMS:
THE CHROMATOGRAPHIC REVOLUTION 296 1. GAS CHROMATOGRAPHY 296 2.
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY 298 3. MISCELLANEOUS 300
REFERENCES 302 CHAPTER 12 PRECLINICAL PHARMACOLOGY OF BIGUANIDES N.F.
WIERNSPERGER. WITH 13 FIGURES 305 A. INTRODUCTION 305 B. ABSORPTION AND
DISTRIBUTION 306 I. ABSORPTION 306 II. TISSUE DISTRIBUTION 306 C.
EFFICACY 308 D. GENERAL PHARMACOLOGY 309 I. BLOOD PRESSURE 309 II. VARIA
309 III. HORMONES 310 IV. ANTITUMORAL PROPERTIES 310 V.
VASCULOPROTECTIVE EFFECTS 310 1. MACROCIRCULATION 310 2.
MICROCIRCULATION 312 3. HYPERTENSION 313 CONTENTS XXI E. ORGAN
PHARMACOLOGY 314 I. GASTROINTESTINAL TRACT 314 1. IN VITRO 7.. 314 2. IN
VIVO 316 II. PANCREATIC HORMONE SECRETION 318 1. IN VITRO 318 2. IN VIVO
319 III. LIVER 319 1. IN VITRO 319 2. IN VIVO 321 IV. ADIPOSE TISSUE 323
1. IN VITRO 323 2. IN VIVO 323 V. SKELETAL MUSCLE/HEART 324 1. IN VITRO
324 2. IN VIVO 324 VI. OTHER TISSUES 327 1. BLOOD CELLS 327 2. VARIA 327
F. LIPID METABOLISM 328 I. LIPOGENESIS 328 II. LIPOLYSIS 328 III. FATTY
ACIDS 328 IV. TRIGLYCERIDES 329 V. LIPOPROTEINS 329 VI. CHOLESTEROL 329
G. CELLULAR EFFECTS 330 I. NEED FOR INSULIN? 330 II. POTENTIATION OF
INSULIN ACTIONS 330 III. MECHANISMS OF INSULIN POTENTIATION 332 1.
PLASMA INSULIN 333 2. INSULIN RECEPTOR BINDING/PHOSPHORYLATION 333 3.
POSTRECEPTOR MECHANISMS 334 4. MECHANISMS NOT LINKED WITH POTENTIATION
334 5. INSULIN-INDEPENDENT EFFECTS 336 IV. BIGUANIDES: MEMBRANE-ACTIVE
DRUGS 336 1. SUPPORTING ARGUMENTS 337 2. MEMBRANE BINDING/CELLULAR
UPTAKE 337 V. INTRACELLULAR EFFECTS 341 VI. CONCLUSIONS 342 H.
CONCLUSIONS 343 REFERENCES 344 XXII CONTENTS CHAPTER 13 TOXICOLOGY OF
BIGUANIDES F. SCHMIDT, F. HARTIG, W. REBEL, AND P. OCHLICH. WITH 3
FIGURES .. 359 A. INTRODUCTION 359 B. GENERAL PHARMACOLOGY AND
TOXICOLOGY 359 C. ACUTE AND CHRONIC TOXICITY 360 I. PHENETHYLBIGUANIDE
(PHENFORMIN) 360 1. BIOCHEMICAL DEVIATIONS IN BLOOD SERUM AND LIVER
MITOCHONDRIA 360 2. SERUM LEVELS AND ORGAN DISTRIBUTION (KIDNEYS,
DUODENUM, LIVER AND ORGANELLES) 363 3. ACUTE TOXICITY 365 4. CHRONIC
TOXICITY 366 II. BUTYLBIGUANIDE (BUFORMIN) 367 1. ACUTE TOXICITY 367 2.
CHRONIC TOXICITY 367 III. DIMETHYLBIGUANIDE (METFORMIN) 367 1. ACUTE
TOXICITY 367 2. SUBCHRONIC AND CHRONIC TOXICITY 368 3. MUTAGENICITY,
FERTILITY AND TERATOGENICITY 369 4. CARCINOGENICITY STUDIES 369 D.
COMPARATIVE EVALUATIONS AND CRITICAL REMARKS 370 REFERENCES 370 CHAPTER
14 CLINICAL PHARMACOLOGY OF BIGUANIDES L.S. HERMANN. WITH 1 FIGURE * 373
A. INTRODUCTION 373 B. PHARMACODYNAMICS 374 I. ANTIHYPERGLYCAEMIC EFFECT
374 II. WEIGHT-STABILIZING EFFECT 377 III. LIPID-LOWERING EFFECT 378 1.
TRIGLYCERIDES, CHOLESTEROL AND LIPOPROTEINS 378 2. FREE FATTY ACIDS AND
GLYCEROL 380 IV. INSULIN-SENSITIZING EFFECT 381 1. INSULIN SECRETION 381
2. INSULIN LEVELS 382 3. INSULIN ACTION AND INSULIN RESISTANCE 383 V.
VASCULAR EFFECTS 388 1. BLOOD PRESSURE AND RENAL EFFECTS 388 2.
FIBRINOLYSIS, HAEMORRHEOLOGY AND THROMBOSIS 388 VI. GASTROINTESTINAL
EFFECTS 390 CONTENTS XXIII C. EFFECTS ON METABOLIC PATHWAYS IN HUMAN
DIABETES 391 I. GLUCOSE METABOLISM 391 II. LACTATE METABOLISM 393 III.
LIPID METABOLISM 394 D. INDICATIONS 395 E. CONTRAINDICATIONS AND
PRECAUTIONS 395 F. COMBINATION THERAPY 396 I. METFORMIN PLUS
SULPHONYLUREA 396 II. METFORMIN PLUS INSULIN 397 G. PHARMACOKINETICS 397
H. SAFETY AND TOLERANCE 398 I. LACTIC ACIDOSIS 398 II. GASTROINTESTINAL
AND OTHER ADVERSE EFFECTS 399 I. INTERACTIONS 400 REFERENCES 400 SECTION
III: GLUCOSIDASE INHIBITORS CHAPTER 15 CHEMISTRY AND STRUCTURE-ACTIVITY
RELATIONSHIPS OF GLUCOSIDASE INHIBITORS B. JUNGE, M. MATZKE, AND J.
STOLTEFUSS. WITH 63 FIGURES 411 A. INTRODUCTION 411 B.
PSEUDOGLUCOSYLAMINES 412 I. VALIDAMINE, VALIENAMINE, AND VALIOLAMINE 412
II. N-SUBSTITUTED VALIOLAMINE DERIVATIVES 417 III. ACARVIOSIN
DERIVATIVES 419 IV. ACARBOSE 421 V. HIGHER PSEUDO-OLIGOSACCHARIDES 426
C. POLYHYDROXYPIPERIDINES AND POLYHYDROXYPYRROLIDINES 427 I. NOJIRIMYCIN
427 II. 1-DEOXYNOJIRIMYCIN 429 III. N-SUBSTITUTED DERIVATIVES OF
1-DEOXYNOJIRIMYCIN 432 IV. BRANCHED AND CHAIN-EXTENDED DEOXYNOJIRIMYCIN
DERIVATIVES 444 1. DERIVATIVES BRANCHED AT C-L 444 2. DERIVATIVES
BRANCHED AT C-5 446 3. DERIVATIVES CHAIN-EXTENDED AT C-6 .... 449 V.
DEOXY, AMINO, AND HALOGEN DERIVATIVES 450 VI. POLYHYDROXYPIPERIDINES
WITH ALTERED CONFIGURATION 453 VII. BICYCLIC DERIVATIVES OF
DEOXYNOJIRIMYCIN 454 XXIV CONTENTS 1. CASTANOSPERMINE 454 2.
CASTANOSPERMINE DERIVATIVES 457 VIII. POLYHYDROXYPYRROLIDINES 460 1.
MONOCYCLIC PYRROLIDINE DERIVATIVES 460 2. BICYCLIC PYRROLIDINE
DERIVATIVES 465 REFERENCES 467 CHAPTER 16 ANALYTICAL METHODS OF
DETERMINATION OF GLUCOSIDASE INHIBITORS H.J. PLOSCHKE, H. SCHLECKER, S.
SEIP, AND C. WUNSCHE. WITH 5 FIGURES 483 A. CHROMATOGRAPHIC TECHNIQUES
483 I. ANALYTICAL METHODS 483 II. PREPARATIVE METHODS 484 1.
REVERSE-PHASE CHROMATOGRAPHY 485 2. ION-EXCHANGE CHROMATOGRAPHY 487 3.
SIZE-EXCLUSION CHROMATOGRAPHY 487 4. ADSORPTION CHROMATOGRAPHY 488 5.
CRAIG DISTRIBUTION 488 6. DETECTION 490 B. SPECTROSCOPIC TECHNIQUES 490
I. NUCLEAR MAGNETIC RESONANCE 490 II. MASS SPECTROMETRY 492 REFERENCES -
494 CHAPTER 17 PHARMACOLOGY OF GLUCOSIDASE INHIBITORS W. PULS. WITH 3
FIGURES 497 A. INTRODUCTION 497 B. INTESTINAL DIGESTION OF DIETARY DI-,
OLIGO- AND POLYSACCHARIDES BY A-GLUCOSIDASES 497 C. EXPLORATORY
INVESTIGATIONS ON THE FEASIBILITY OF A-GLUCOSIDASE INHIBITION 498 D.
PRIMARY EFFECTS OF GLUCOSIDASE INHIBITORS 500 E. SECONDARY EFFECTS OF
GLUCOSIDASE INHIBITORS 501 I. INVESTIGATIONS TO EVALUATE THE POTENCY OF
GLUCOSIDASE INHIBITORS 501 II. BLOOD GLUCOSE AND PLASMA INSULIN 503 1.
SINGLE-DOSE STUDIES 503 2. REPEATED ADMINISTRATION 505 CONTENTS XXV III.
LIPID METABOLISM 508 1. BLOOD LIPIDS 508 2. TISSUE LIPIDS 509 IV.
PROTEIN METABOLISM 511 V. HORMONES 512 1. PANCREATIC INSULIN 512 2.
CATECHOLAMINES AND THYROID HORMONES 513 3. OTHER HORMONES 513 VI.
VITAMINS AND TRACE METALS 514 VII. EXOCRINE PANCREAS 514 VIII. SMALL AND
LARGE BOWEL 515 1. WEIGHT, LENGTH AND MICROFLORA 515 2. ENZYME ACTIVITY
ALTERATIONS IN THE SMALL INTESTINE .... 517 3. ENTEROHORMONES IN THE
INTESTINAL GUT WALL 518 IX. LIVER 519 1. GLYCOGEN 519 2. LIPIDS 520 X.
HEART 522 XI. SKELETAL MUSCLE 522 XII. DANGEROUS LATE COMPLICATIONS 523
1. NEPHROPATHY 523 2. NEUROPATHY 524 3. RETINAL MICROANGIOPATHY 525
REFERENCES 525 CHAPTER 18 GENERAL PHARMACOLOGY OF GLUCOSIDASE INHIBITORS
W. PULS 535 A. INTRODUCTION 535 B. NEUROPHARMACOLOGICAL STUDIES 535 C.
CARDIOVASCULAR/RESPIRATORY STUDIES 536 D. GASTROINTESTINAL FUNCTION
STUDIES 536 E. HAEMATOLOGICAL STUDIES 537 F. ANTIGENIC, ANTIALLERGIC AND
PULMONARY ACTIVITY 537 G. ANTIBACTERIAL, ANTIMYCOTIC AND ANTIPARASITIC
ACTIVITY 537 H. OTHER STUDIES 537 REFERENCES 538 XXVI CONTENTS CHAPTER
19 PHARMACOKINETICS AND METABOLISM OF GLUCOSIDASE INHIBITORS H.P. KRAUSE
AND H.J. AHR. WITH 4 FIGURES 541 A. INTRODUCTION 541 B. ACARVIOSIN
DERIVATIVES 541 I. ACARBOSE 541 1. INTRODUCTION 541 2. DETERMINATION
METHODS 542 3. ABSORPTION 542 4. PLASMA CONCENTRATIONS 543 5. PROTEIN
BINDING 543 6. DISTRIBUTION 543 7. METABOLISM 544 8. EXCRETION 544 C.
VALIOLAMINE DERIVATIVES 545 I. AO-128 545 1. INTRODUCTION 545 2.
DETERMINATION METHODS 545 3. ABSORPTION 546 4. PLASMA CONCENTRATIONS OF
TOTAL RADIOACTIVITY 546 5. PLASMA CONCENTRATIONS OF UNCHANGED AO-128 546
6. DISTRIBUTION 546 7. METABOLISM 547 8. EXCRETION 547 D.
DEOXYNOJIRIMYCIN-DERIVATIVES 547 I. MIGLITOL 547 1. INTRODUCTION 547 2.
DETERMINATION METHODS 548 3. ABSORPTION 548 4. PLASMA CONCENTRATIONS 548
5. PROTEIN BINDING 548 6. DISTRIBUTION 549 7. METABOLISM 549 8.
EXCRETION 549 II. EMIGLITATE 549 1. INTRODUCTION 549 2. ABSORPTION 550
3. PLASMA CONCENTRATIONS 550 4. DISTRIBUTION 550 5. METABOLISM 550 6.
EXCRETION ; 551 III. OTHER DEOXYNOJIRIMYCIN DERIVATIVES 551 1.
1-DEOXYMANNOJIRIMYCIN 551 2. AF-METHYL-1 -DEOXYNOJIRIMYCIN 552 CONTENTS
XXVII E. COMPARATIVE DISCUSSION 552 REFERENCES 554 CHAPTER 20 TOXICOLOGY
OF GLUCOSIDASE INHIBITORS E.M. BOMHARD. WITH 2 FIGURES 557 A. ACARBOSE
557 I. GENERAL TOXICOLOGY 557 1. ACUTE TOXICITY ... . 557 2. SUBACUTE
INTRAVENOUS TOXICITY 557 3. SUBCHRONIC ORAL TOXICITY 558 4. CHRONIC
TOXICITY 559 II. REPRODUCTION TOXICOLOGY 560 1. FERTILITY AND GENERAL
REPRODUCTIVE PERFORMANCE IN RATS 560 2. EMBRYOTOXICITY/TERATOGENICITY IN
RATS 560 3. PERI-/POSTNATAL STUDY IN RATS 560 4.
EMBRYOTOXICITY/TERATOGENICITY IN RABBITS 561 III.
GENOTOXICITY/MUTAGENICITY 561 IV. CARCINOGENICITY 561 1. RAT 561 2.
HAMSTER 569 3. LOW-CARBOHYDRATE/EMIGLITATE LIFETIME CARCINOGENICITY
STUDY IN SPRAGUE-DAWLEY RATS 571 V. TOXICOKINETICS 571 VI. SPECIAL
STUDIES 573 1. GLYCOGEN STORAGE IN RATS 573 2. CELL PROLIFERATION IN
KIDNEY CORTEX 574 3. ELECTRON MICROSCOPIC INVESTIGATIONS 575 4.
INVESTIGATIONS OF EFFECTS ON ENDOCRINIUM 575 5. INTERACTION WITH OTHER
ORAL ANTIDIABETICS 575 VII. ASSESSMENT OF THE CARCINOGENIC POTENTIAL OF
ACARBOSE .... 576 1. SIGNIFICANCE OF LEYDIG CELL TUMOURS 576 2.
SIGNIFICANCE OF EPITHELIAL KIDNEY TUMOURS IN SPRAGUE-DAWLEY RATS 577 B.
EMIGLITATE 579 I. GENERAL TOXICOLOGY 579 1. ACUTE TOXICITY 579 2.
SUBACUTE TOXICITY 580 3. SUBCHRONIC TOXICITY 580 4. CHRONIC TOXICITY 581
II. REPRODUCTION TOXICOLOGY 582 XXVIII CONTENTS 1. FERTILITY AND GENERAL
REPRODUCTIVE PERFORMANCE IN RATS : 582 2. EMBRYOTOXICITY/TERATOGENICITY
IN RATS 582 3. EMBRYOTOXICITY/TERATOGENICITY IN RABBITS 582 III.
GENOTOXICITY/MUTAGENICITY 582 IV. CARCINOGENICITY 582 1. RAT 582 2.
MOUSE 584 V. TOXICOKINETICS 584 VI. SPECIAL STUDIES 584 C. MIGLITOL 585
I. GENERAL TOXICOLOGY 585 1. ACUTE TOXICITY 585 2. SUBACUTE TOXICITY 585
3. SUBCHRONIC TOXICITY 586 4. CHRONIC TOXICITY 586 II. REPRODUCTION
TOXICOLOGY . 587 1. FERTILITY AND GENERAL REPRODUCTIVE PERFORMANCE IN
RATS 587 2. EMBRYOTOXICITY/TERATOGENICITY IN RATS 587 3. PERI-/POSTNATAL
STUDY IN RATS 587 4. EMBRYOTOXICITY/TERATOGENICITY IN RABBITS 587 III.
GENOTOXICITY/MUTAGENICITY 588 IV. CARCINOGENICITY 588 1. RAT 588 2.
MOUSE- 588 V. TOXICOKINETICS 588 VI. SPECIAL STUDIES 591 D. VOGLIBOSE
592 I. GENERAL TOXICOLOGY 592 1. ACUTE TOXICITY 592 2. SUBACUTE TOXICITY
592 3. SUBCHRONIC TOXICITY 593 4. CHRONIC TOXICITY 595 II. REPRODUCTION
TOXICOLOGY 596 1. FERTILITY AND GENERAL REPRODUCTIVE PERFORMANCE IN RATS
596 2. EMBRYOTOXICITY/TERATOGENICITY IN RATS 596 3. PERI-/POSTNATAL
STUDY IN RATS 597 4. EMBRYOTOXICITY/TERATOGENICITY IN RABBITS 598 5.
PERI-/POSTNATAL STUDY IN RATS FED ON A GLUCOSE DIET 598 III.
GENOTOXICITY/MUTAGENICITY 599 IV. CARCINOGENICITY 599 1. RAT 599 2.
MOUSE 600 CONTENTS XXIX V. TOXICOKINETICS 601 VI. SPECIAL STUDIES 601 1.
ANTIGENICITY IN GUINEA PIGS AND MICE 601 2. EFFECT OF DIETARY
CARBOHYDRATES ON THE ORAL TOXICITY IN RATS 601 3. EFFECT OF LOW-PROTEIN
DIET ON PLASMA TRANSAMINASES IN RATS 602 E. CASTANOSPERMINE 602 I.
GENERAL TOXICOLOGY 602 1. ACUTE/SUBACUTE TOXICITY 602 II. REPRODUCTION
TOXICOLOGY 603 III. GENOTOXICITY/MUTAGENICITY 603 IV. CARCINOGENICITY
603 V. TOXICOKINETICS 603 VI. SPECIAL STUDIES 603 F. COMMON
TOXICOLOGICAL CHARACTERISTICS OF GLUCOSIDASE INHIBITORS 604 I. REDUCED
GLUCOSE UTILIZATION 605 II. LYSOSOMAL GLYCOGEN STORAGE 606 III.
ACCUMULATION OF UNDIGESTED CARBOHYDRATES IN THE LARGE INTESTINE , 607
REFERENCES 608 CHAPTER 21 CLINICAL PHARMACOLOGY OF GLUCOSIDASE
INHIBITORS E. BRENDEL AND W. WINGENDER. WITH 4 FIGURES 611 A. ACARBOSE
611 I. INTRODUCTION 611 II. PHARMACODYNAMICS 611 1. EFFECTS ON BLOOD
SUGAR AND INSULIN 611 2. EFFECTS ON GASTROINTESTINAL HORMONES AND
EXOCRINE PANCREATIC FUNCTION 613 3. EFFECTS ON LIPIDS AND LIPOPROTEINS
614 III. PHARMACOKINETICS 614 IV. SAFETY AND TOLERABILITY 616 V.
INTERACTIONS 617 B. DEOXYNOJIRIMYCIN DERIVATIVES (MIGLITOL, EMIGLITATE)
618 I. INTRODUCTION 618 II. PHARMACODYNAMICS 619 1. EFFECT ON BLOOD
SUGAR AND INSULIN 619 2. EFFECTS ON GASTROINTESTINAL HORMONES 623 3.
EFFECTS ON LIPIDS 623 III. PHARMACOKINETICS 624 IV. SAFETY AND
TOLERABILITY 625 XXX , CONTENTS V. INTERACTIONS 626 C. OTHER GLUCOSIDASE
INHIBITORS 626 I. INTRODUCTION 626 II. PHARMACODYNAMICS 626 REFERENCES
628 CHAPTER 22 CLINICAL EVALUATION OF GLUCOSIDASE INHIBITORS R.H. TAYLOR
AND E.M. BARDOLPH 633 A. INTRODUCTION 633 I. CARBOHYDRATE DIGESTION 633
II. DIET AND GLUCOSIDASE INHIBITORS 634 III. ROLE OF GLUCOSIDASE
INHIBITORS IN DIABETES 635 B. ACARBOSE 635 I. STUDIES IN TYPE I DIABETES
636 II. STUDIES IN TYPE II DIABETES 637 1. CLINICAL TRIALS 637 2. EFFECT
ON LIPIDS 638 3. STUDIES COMPARING EFFECTS WITH OTHER ANTIDIABETIC
AGENTS 639 III. OTHER CLINICAL STUDIES 641 C. DEOXYNOJIRIMYCIN
DERIVATIVES 641 I. STUDIES IN TYPE I DIABETES 642 II. STUDIES IN TYPE II
DIABETES 643 D. OTHER GLUCOSIDASE INHIBITORS 644 E. CONCLUSIONS 645
REFERENCES 646 CHAPTER 23 ORAL ANTIDIABETIC DRUGS IN RESEARCH AND
DEVELOPMENT H. BISCHOFF AND H.E. LEBOVITZ. WITH 11 FIGURES 651 A.
INTRODUCTION 651 B. STIMULATION AND MODULATION OF INSULIN SECRETION 652
I. DEPOLARIZATION OF THE B-CELL MEMBRANE 653 1. INHIBITORS OF THE
ATP-SENSITIVE K + CHANNEL 653 A) SULFONYLUREA DERIVATIVES 653 B) BENZOIC
ACID DERIVATIVES 655 C) GUANIDINE DERIVATIVES 656 D) 2-SUBSTITUTED
IMIDAZOLINE DERIVATIVES . 657 2. COMPOUNDS WITH UNCERTAIN SITES OF
ACTION 659 II. A 2 -ADRENOCEPTOR ANTAGONISM 661 III. CA 2+ CHANNEL
MODULATION 662 CONTENTS , XXXI C. SUPPRESSION OF HEPATIC GLUCOSE
PRODUCTION 663 I. INHIBITION OF FATTY ACID OXIDATION 664 1. INHIBITORS
OF CARNITINE ACYLCARNITINE TRANSLOCASE: HYDRAZONOPROPIONIC ACID
DERIVATIVES 664 A) PHARMACOLOGICAL PROPERTIES 665 B) EFFECT ON
GLUCONEOGENESIS AND MODE OF ACTION ... 666 C) CLINICAL STUDIES 668 2.
INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE I 668 A) PHARMACOLOGY AND
EFFECTS ON GLUCONEOGENESIS .... 668 A) 2-OXIRANE CARBOXYLIC ACID
DERIVATIVES 668 P) DIOXOLANE DERIVATIVE 670 Y) B-AMINOBETAINE STRUCTURES
670 B) PHARMACOKINETICS AND TOXICOLOGY 671 C) CLINICAL STUDIES 672 D.
ENHANCEMENT OF INSULIN ACTION 673 E. MIMICKING OF INSULIN ACTION 678 F.
PREVENTION OF DELETERIOUS EFFECTS CAUSED BY GLUCOSE 680 I. ALDOSE
REDUCTASE INHIBITORS 681 II. AMINOGUANIDINE: AN INHIBITOR OF ADVANCED
GLYCATION END PRODUCT FORMATION 684 REFERENCES 685 CHAPTER 24 NEW
APPROACHES FOR THE TREATMENT OF DIABETES MELLITUS J.M. AMATRUDA AND M.L:
MCCALEB 697 A. PREVENTION 697 I. NON-INSULIN-DEPENDENT DIABETES MELLITUS
697 II. INSULIN-DEPENDENT DIABETES MELLITUS 698 B. OBESITY 700 I.
CENTRAL MECHANISMS 701 II. PERIPHERAL MECHANISMS 703 1. INCREASED ENERGY
EXPENDITURE 703 2. DECREASED FAT ABSORPTION 704 C. INSULIN SENSITIZERS
704 I. RATIONALE 704 II. SPECIFIC TARGETS 705 III. AMYLIN AND AMYLIN
BLOCKERS 706 D. ALTERNATIVE INSULIN DELIVERY 707 E. GENE THERAPY 709
REFERENCES 710 SUBJECT INDEX 715
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV010484019 |
| callnumber-first | Q - Science |
| callnumber-label | QP905 |
| callnumber-raw | QP905 RC661.A1 |
| callnumber-search | QP905 RC661.A1 |
| callnumber-sort | QP 3905 |
| callnumber-subject | QP - Physiology |
| classification_rvk | VT 5200 XI 1701 YC 6800 |
| classification_tum | MED 441f MED 970f MED 920f |
| ctrlnum | (OCoLC)32859225 (DE-599)BVBBV010484019 |
| dewey-full | 615/.1 616.4/62061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics 616 - Diseases |
| dewey-raw | 615/.1 616.4/62061 |
| dewey-search | 615/.1 616.4/62061 |
| dewey-sort | 3615 11 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02795nam a2200745 cb4500</leader><controlfield tag="001">BV010484019</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20140403 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">951113s1996 gw ad|| |||| 00||| eng d</controlfield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">944730914</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3540589902</subfield><subfield code="9">3-540-58990-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)32859225</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV010484019</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-12</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-11</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP905</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC661.A1</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615/.1</subfield><subfield code="2">20</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.4/62061</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VT 5200</subfield><subfield code="0">(DE-625)147743:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 1701</subfield><subfield code="0">(DE-625)152977:12907</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">YC 6800</subfield><subfield code="0">(DE-625)153250:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MED 441f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MED 970f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QV 4</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">MED 920f</subfield><subfield code="2">stub</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Oral antidiabetics</subfield><subfield code="b">[with 85 tables]</subfield><subfield code="c">contributors H. J. Ahr ... Ed. Jochen Kuhlmann ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin [u.a.]</subfield><subfield code="b">Springer</subfield><subfield code="c">1996</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXXI, 732 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Handbook of experimental pharmacology</subfield><subfield code="v">119</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Hypoglycaemic Properties</subfield><subfield code="2">cabt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antidiabetica</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Orale toediening</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Diabetes Mellitus, Type 2</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypoglycemic Agents</subfield><subfield code="x">pharmacology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypoglycemic Agents</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypoglycemic agents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Non-insulin-dependent diabetes</subfield><subfield code="x">Chemotherapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Diabetes mellitus</subfield><subfield code="0">(DE-588)4070446-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Antidiabetikum</subfield><subfield code="0">(DE-588)4002265-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Orale Applikation</subfield><subfield code="0">(DE-588)4202348-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="a">Orales Antidiabetikum</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Antidiabetikum</subfield><subfield code="0">(DE-588)4002265-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Orale Applikation</subfield><subfield code="0">(DE-588)4202348-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Diabetes mellitus</subfield><subfield code="0">(DE-588)4070446-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Pharmakotherapie</subfield><subfield code="0">(DE-588)4076066-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="2" ind2="0"><subfield code="a">Antidiabetikum</subfield><subfield code="0">(DE-588)4002265-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="2" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="3" ind2="0"><subfield code="a">Orales Antidiabetikum</subfield><subfield code="A">f</subfield></datafield><datafield tag="689" ind1="3" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kuhlmann, Jochen</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ahr, Hans Jürgen</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Handbook of experimental pharmacology</subfield><subfield code="v">119</subfield><subfield code="w">(DE-604)BV002390716</subfield><subfield code="9">119</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006986806&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-006986806</subfield></datafield></record></collection> |
| genre | Orales Antidiabetikum gnd |
| genre_facet | Orales Antidiabetikum |
| id | DE-604.BV010484019 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T17:53:17Z |
| institution | BVB |
| isbn | 3540589902 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-006986806 |
| oclc_num | 32859225 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-12 DE-20 DE-11 DE-188 DE-578 |
| owner_facet | DE-19 DE-BY-UBM DE-355 DE-BY-UBR DE-12 DE-20 DE-11 DE-188 DE-578 |
| physical | XXXI, 732 S. Ill., graph. Darst. |
| publishDate | 1996 |
| publishDateSearch | 1996 |
| publishDateSort | 1996 |
| publisher | Springer |
| record_format | marc |
| series | Handbook of experimental pharmacology |
| series2 | Handbook of experimental pharmacology |
| spelling | Oral antidiabetics [with 85 tables] contributors H. J. Ahr ... Ed. Jochen Kuhlmann ... Berlin [u.a.] Springer 1996 XXXI, 732 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Handbook of experimental pharmacology 119 Drugs cabt Hypoglycaemic Properties cabt Antidiabetica gtt Orale toediening gtt Diabetes Mellitus, Type 2 drug therapy Hypoglycemic Agents pharmacology Hypoglycemic Agents therapeutic use Hypoglycemic agents Non-insulin-dependent diabetes Chemotherapy Diabetes mellitus (DE-588)4070446-4 gnd rswk-swf Antidiabetikum (DE-588)4002265-1 gnd rswk-swf Orale Applikation (DE-588)4202348-8 gnd rswk-swf Pharmakotherapie (DE-588)4076066-2 gnd rswk-swf Orales Antidiabetikum gnd rswk-swf Antidiabetikum (DE-588)4002265-1 s Orale Applikation (DE-588)4202348-8 s DE-604 Diabetes mellitus (DE-588)4070446-4 s Pharmakotherapie (DE-588)4076066-2 s Orales Antidiabetikum f Kuhlmann, Jochen Sonstige oth Ahr, Hans Jürgen Sonstige oth Handbook of experimental pharmacology 119 (DE-604)BV002390716 119 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006986806&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Oral antidiabetics [with 85 tables] Handbook of experimental pharmacology Drugs cabt Hypoglycaemic Properties cabt Antidiabetica gtt Orale toediening gtt Diabetes Mellitus, Type 2 drug therapy Hypoglycemic Agents pharmacology Hypoglycemic Agents therapeutic use Hypoglycemic agents Non-insulin-dependent diabetes Chemotherapy Diabetes mellitus (DE-588)4070446-4 gnd Antidiabetikum (DE-588)4002265-1 gnd Orale Applikation (DE-588)4202348-8 gnd Pharmakotherapie (DE-588)4076066-2 gnd |
| subject_GND | (DE-588)4070446-4 (DE-588)4002265-1 (DE-588)4202348-8 (DE-588)4076066-2 |
| title | Oral antidiabetics [with 85 tables] |
| title_auth | Oral antidiabetics [with 85 tables] |
| title_exact_search | Oral antidiabetics [with 85 tables] |
| title_full | Oral antidiabetics [with 85 tables] contributors H. J. Ahr ... Ed. Jochen Kuhlmann ... |
| title_fullStr | Oral antidiabetics [with 85 tables] contributors H. J. Ahr ... Ed. Jochen Kuhlmann ... |
| title_full_unstemmed | Oral antidiabetics [with 85 tables] contributors H. J. Ahr ... Ed. Jochen Kuhlmann ... |
| title_short | Oral antidiabetics |
| title_sort | oral antidiabetics with 85 tables |
| title_sub | [with 85 tables] |
| topic | Drugs cabt Hypoglycaemic Properties cabt Antidiabetica gtt Orale toediening gtt Diabetes Mellitus, Type 2 drug therapy Hypoglycemic Agents pharmacology Hypoglycemic Agents therapeutic use Hypoglycemic agents Non-insulin-dependent diabetes Chemotherapy Diabetes mellitus (DE-588)4070446-4 gnd Antidiabetikum (DE-588)4002265-1 gnd Orale Applikation (DE-588)4202348-8 gnd Pharmakotherapie (DE-588)4076066-2 gnd |
| topic_facet | Drugs Hypoglycaemic Properties Antidiabetica Orale toediening Diabetes Mellitus, Type 2 drug therapy Hypoglycemic Agents pharmacology Hypoglycemic Agents therapeutic use Hypoglycemic agents Non-insulin-dependent diabetes Chemotherapy Diabetes mellitus Antidiabetikum Orale Applikation Pharmakotherapie Orales Antidiabetikum |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006986806&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV002390716 |
| work_keys_str_mv | AT kuhlmannjochen oralantidiabeticswith85tables AT ahrhansjurgen oralantidiabeticswith85tables |